Member Info for roleybirkin

Fantastic market knowledge MasterRSI.
Are you a trader?
Do you work in The City?

The warrants are two years and I believe at 28.5p. The warrants have yet to be delivered as they generally take 2nd place to the new placing shares being issued.
The booking of placing shares only took place Thursday with settlement 1st June so it may be difficult for new shares to be sold.
I will be holding and very happy to get a decent allocation at 22p and it is the warrant's that will be extremely valuable to both the company and holders.

Glassdoor is known for good and bad posts and generally the bad can be quite damning to any company.
At the end of December there were three very damning write ups by Bidstack staff/ex staff.
Those three all disappeared also but I did take a screen shot at the time.
I am aware that companies can involve their legal teams to have bad posts removed especially if they are clear in there mind as to who posted them.
All non news quite frankly.

Is that you holdlong. Nice to see back.
Odd state of affairs.
Ho hum.
Interesting presentation 13 days ago. Seems like an age ago now. Guess it was.

That's what MM's do when they see sellers. Lower the price...

True finnovator, but given the year is now forecast at £4m it is difficult in my view for 1H 21 to be above 2H 20 by any meaningful number.
I think we may see 1H 21 at around £1.25m (up an316%) and 2H 21 coming in at £2.75m (up 96%)
Just my views and good for people to challenge and counter.

Yet more great news for on-line sales.
Amazon has been in the pipeline for some time and it is still hoped that a June launch can happen.
Will be excellent in driving sales 2nd half of 2021.

So the Chairman talked hard numbers..... as follows:-
- H&B revenue was at £11/12k per week.
- Love Hemp spent £300k marketing campaign across a year and
- H&B revenues have risen to £70k per week
- Annualised come in at £3.64m a year from one outlet
- Up to a 536% rise in sales

Now that was a marketing budget well spent.

clark777,
Year end was around £2.35m cash.
R&D tax credit January guessing around £800k plus as
end January 2021 cash was £2.76m (or thereabouts)
Forecast loss of £7.9m (Stifel latest broker note) which equates to a loss of £658,333 per month
So end Month cash should look like this:-
- end Feb £2.1m
- end Mar £1.44m
- end Apr £785k
- end May £126k

Clearly, the above using known released numbers so not fully accurate but likely close especially as revenues are 2nd half weighted so 1st 21 revenues are down on 2nd half 2020.

Also, a further R&D credit is due by end June for year end Dec 2020 but likely smaller than January's.

They seem to be on fumes so I gather they have been presenting through their brokers for last two weeks.

Positive news on the continued roll out of the Versalab brand.

Great progress and a great cause.

I think excellent news.
Great progress.

The NAV has fallen below the 100p I was desperate for it to hold.
Not been the best couple of weeks but happy to hold for the long term.

The issue I see is that trust in the management and the NAV are two things.
The markets look at NAV and will mark the share price accordingly, and unfortunately we are likely to see sub 100p tomorrow.
The trust in the management is why shareholders will likely hold and see this 'crash' through...

troublesome - no motive. Just unfortunately a fact.
And a rather disappointing fact at that.

So the board of Novacyt need to do something to either support shareholder confidence or consider merger or sale to a larger group to deliver shareholder value
--------------------------------------------------------------------------------------

My view is the company may be looking for a sale. We shall see in the coming year or so.

Novacyt are in other branches of Diagnostics but with demand being so high you can't not service this sector
--------------------------------------------------------------------------------------

Revenues pre Covid were low and as yet I have not seen any diagnostic company acquisitions that are delivering revenues.
Happy to be corrected on this point?

COVID is not going away,
-------------------------------------------------------------------------------------

That is your opinion and I certainly think it will take some time, but I know a lot of people who may disagree with you.

@roleybirkin
Not sure why i'm bothering to respond to you as you are one of the biggest de-rampers or shorter's here
-------------------------------------------------------------------------------------------------------

Interesting 5 posts in last 90 days on Ncyt?
I just try to give balanced opinions. No more.

The issue that analysts are having is IF Covid vaccination works and testing falls away then revenues fall to £10m or less.
That is the issue here. How do you value any business on future revenues when they are clearly unassured?
A re-rate comes as and when the board utilise the cash in acquiring diagnostics companies away from covid.